BAX and cancer: Our findings highlight a potential new combinatorial strategy aimed at potentiating the pro-apoptotic activity of Venetoclax with a natural and well-tolerated compound, which could overcome potential resistance mechanisms to Venetoclax used as single agent (44).Several classes of small molecules have been identified in the last decade that selectively activate Bax to induce apoptosis, which demonstrated good in vitro but moderate in vivo anti-cancer activity (45, 46).